After the FDA Webcast: Discussing Drug Development and Clinical Trial Strategies

S2 E5.3 – After the FDA Webcast: Discussing Drug Development and Clinical Trial Strategies

The Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of theFDA Webcast that centered on drug development and clinical trial strategies
()

The panel discussed key takeaways from the FDA webcast on NASH Drug Development on the subjects of clinical trial design and development strategies. Much discussion centered around parallel clinical trials for F2/F3 and controlled cirrhotic patients, both in terms of rethinking endpoints (is it sufficient to “halt” progression?) and designing sets of parallel trials to the sponsor’s best benefit. Another key topic involved combination of combination therapies and practical issues around moving to combination approvals prior to having an acceptable set of monotherapies available. The third major area of interest involved length of trial for newer medications that are producing dramatic Phase 2 results in as little as 12-16 weeks.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Advance Notification

We send out emails to notify our followers before we post on social media, and often it's before your podcast app is updated!